Melanoma Information

Sentinel Node Biopsy for Thin Melanomas: Which Patient Should Be Considered?
Christopher A. Puleo, PA-C; Jane L. Messina, MD; Adam I. Riker, MD; L. Frank Glass, MD; Christopher Nelson, MD; C. Wayne Cruse, MD; Timothy M. Johnson, MD; Vernon K. Sondak, MD

Head and Neck Melanoma
Matthew A. Kienstra, MD; Tapan A. Padhya, MD

Choices in Adjuvant Therapy for Melanoma
David H. Lawson, MD

Cutaneous Melanoma: Prognostic Factors
Jade Homsi, MD, Mohammed Kashani-Sabet, MD, Jane L. Messina, MD, Adil Daud, MD

Chemoprevention of Melanoma: Theoretical and Practical Considerations
Marie-France Demierre, MD, FRCPC, Vernon K. Sondak, MD

Vaccines for Melanoma
C. Dean Buckner, MD

Chemo-immunotherapy Not Better Than Chemotherapy Alone for Metastatic Melanoma (11/17/2008)
Researchers affiliated with Eastern Cooperative Oncology Group trial 3695 have reported that the addition of interleukin-2 and Interferon-alfa to a regimen of cisplatin, vinblastine, and dacarbazine did not improve survival of patients with metastatic melanoma. The details of this study appeared in an early online publication in the Journal of Clinical Oncology on November 10, 2008.

Adoptive Cell Transfer Following a Myeloablative TBI Regimen Promising for Metastatic Melanoma (11/13/2008)
Researchers from the National Cancer Institute have reported a response rate of 72% following 12 Gy of total body irradiation (TBI) and infusion of autologous tumor infiltrating lymphocytes (TIL) and autologous stem cells in patients with metastatic melanoma. The details of this study appeared in the November 10, 2008 issue of the Journal of Clinical Oncology.

Mediterranean Diet May Protect Against Cutaneous Melanoma (9/29/2008)
Researchers from Italy have reported that the Mediterranean diet may protect persons from cutaneous melanoma. The details of this study appeared in an early online publication in the International Journal of Epidemiology on June 11, 2008.

Dacarbazine plus Pegylated Interferon for Metastatic Melanoma (9/9/2008)
Researchers from Germany have reported that the combination of dacarbazine (DTIC) and pegylated interferon alfa 2a (INF) was well tolerated with a response rate of 24% in the treatment of metastatic melanoma. The details of this study appeared in the September 15, 2008 issue of Cancer.

Radiofrequency Ablation Effective for Lung Tumors (7/22/2008)
Researchers involved in a multicenter international trial have reported that the use of radiofrequency ablation for the treatment of lung cancer or pulmonary metastases provides an effective and safe therapeutic option for selected patients. These results were recently published in the July 7, 2008 issue of Lancet Oncology.